Mandibular Advancement Device Treatment Efficacy is Associated with Polysomnographic Endotypes

Online Supplement

Sara Op de Beeck MSc[*, 1, 3, 6], Marijke Dieltjens PhD[1, 5, 6], Ali Azarbarzin PhD[2], Marc Willemen MSc[3], Johan Verbraecken PhD[1, 3, 4], Marc J. Braem PhD[1, 5], Andrew Wellman PhD[2], Scott A. Sands PhD[2°], Olivier M. Vanderveken PhD[1, 3, 6°]

°Equal contributions

[1] Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium

[2] Division of Sleep and Circadian Disorders, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States,

[3] Multidisciplinary Sleep Disorders Centre, Antwerp University Hospital, Edegem, Belgium,

[4] Department of Pulmonology, Antwerp University Hospital, Edegem, Antwerp, Belgium,

[5] Special Dentistry Care, Antwerp University Hospital, Edegem, Belgium,

[6] ENT, Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium

*Corresponding author:

Sara Op de Beeck
Translational Neurosciences
Faculty of Medicine and Health Sciences
University of Antwerp
Universiteitsplein 1 – D.T.494
2610 Wilrijk
BELGIUM
Email: sara.opdebeeck@uantwerpen.be

Supplemental Figures

Inclusion

Baseline PSG
n = 47 patients consented with AHI ≥ 15/h

Start MAD treatment
75% of maximal protrusion

3-month follow-up PSG
n = 36, 11 patients dropped out

Response:
ΔAHI ≥ 50%

No response:
ΔAHI < 50%

Figure E1: Study protocol.

PSG: polysomnography, MAD: mandibular advancement device, AHI: apnea-hypopnea index